



Funded by
Marie Skłodowska-Curie Programme,
H2020



European Innovative Training Network IMMUTRAIN

15 positions as Early Stage Researcher (PhD student) in the field of Immunotherapy of Cancer

Description: IMMUTRAIN is a research network funded by the Marie Skłodowska-Curie Actions. It comprises nine academic research groups and five industrial partners in nine European countries. The joint goal is to train the next generation of scientists in the field of immunotherapy of cancer. The research objective of IMMUTRAIN is to enhance the efficacy of antibody-based tumor therapies through combination with other immunotherapeutic approaches. Please find further information at www.immutrain.eu

We offer: Cutting edge research projects and training with leading experts in the field of immunotherapy of cancer; employment contract for three years with the benefits of the EU Marie Skłodowska-Curie programme; opportunities for future employment.

We seek: Excellent scientists with a master degree or equivalent in natural sciences or related disciplines (such as medicine or pharmacy); practical skills in modern laboratory work, preferentially combined with experience in animal experiments.

Your profile: You must be within your first four years of research experience after completion of your masters degree or equivalent; you cannot hold a doctoral degree at the time of recruitment; you cannot have spent more than 12 months within the past 36 months in the country where the position you are applying for is located (mobility rule); you must be proficient in the English language both written and spoken (proof required).

Open positions:

- **WP1, Combination of antibodies with adoptive T cell transfer: ESR 1 and ESR 2** (Ludwig-Maximilians-Universität, Germany), **ESR 3** (Nottingham Trent University, UK), **ESR 4** and **ESR 5** (University Hospital Herlev, Region Hovedstaden, Denmark)
- **WP2, New formulations of antibodies to activate immune cells: ESR 6** (Ludwig-Maximilians-Universität, Germany), **ESR 7** (Roche Diagnostics GmbH, Germany), **ESR 8** (Istituto Europeo di Oncologia, Italy)
- **WP3, Combination of antibodies with dendritic cell therapy: ESR 9** (Radboud University Medical Centre, Netherlands), **ESR 10** (Medical University of Innsbruck, Austria)
- **WP4, Combination of antibodies with therapeutic nucleic acids: ESR 11** (Institut Gustave Roussy, France), **ESR 12** (Université de Fribourg, Switzerland), **ESR 13** (Ludwig-Maximilians Universität München, Germany), **ESR 14** and **ESR 15** (Spanish National Cancer Research Center, Spain)

The application procedure will be carried out in compliance with the Code of Conduct for Recruitment and the Charter for Researchers. Please send your application until Friday March 11, 2016 to: <http://portal.graduatecenter-lmu.de/ocgc/itn-immutrain>. We look forward to your application.